Home ProductsMedical Raw Materials

Finasteride Hair Loss Medicine Raw Material 98319-26-7 White Powder For Prostatic Hyperplasia

Certification
Good quality Pharma Raw Material for sales
Good quality Pharma Raw Material for sales
I'm Online Chat Now

Finasteride Hair Loss Medicine Raw Material 98319-26-7 White Powder For Prostatic Hyperplasia

China Finasteride Hair Loss Medicine Raw Material 98319-26-7 White Powder For Prostatic Hyperplasia supplier

Large Image :  Finasteride Hair Loss Medicine Raw Material 98319-26-7 White Powder For Prostatic Hyperplasia

Product Details:

Place of Origin: China
Brand Name: PooChun
Certification: ISO9001 SGS HACCP
Model Number: 98319-26-7

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Packaging Details: 1~10 kg / Al-Pt bag,10kg / 25kg fiber drum
Delivery Time: 1-3days after payment
Payment Terms: T/T, L/C, Western Union, MoneyGram
Supply Ability: 100 ton per Month
Contact Now
Detailed Product Description
CAS: 98319-26-7 Appearance: White Powder
Other Name: Finastid; Propecia; Finpecia; N - Tert - Butyl - 3 - Oxo - 4- Aza - 5α - Androst - 1- En -17β - Carboxamide; Finasteride; Proscar; MK 906 Payment Terms: T/T, Western Union, Paypal, Moneygram
Trade Terms: FOB CNF CIF DAP DDU Shipping: DHL TNT FedEx HKEMS UPS

Finasteride Medicine Raw Material For prostatic hyperplasia male pattern hair loss 98319-26-7

 


Description

 

Finasteride is a 4 - azotypic compound, which is a specific inhibitor of intracellular enzyme - II type 5a - reductase in the process of testosterone metabolism. Benign prostatic hyperplasia or prostatic hypertrophy depends on the conversion of testosterone into dihydrotestosterone in the prostate.

 

This drug can effectively reduce blood and dihydrotestosterone in the prostate gland. The androgen receptor has no affinity for the androgen receptor. Finasteride belong to 5 alpha reductase inhibitors, the mechanism is through its hormone, the inhibition of testosterone into dihydrotestosterone (DHT), increase the shrinkage and improve symptoms of prostate and urinary flow rate, prevention of benign prostatic hyperplasia ( BPH ).

 

 

Function

 

This medication in a long - term efficacy and safety of ( PLESS ), in the study of symptoms of moderate to severe hyperplasia of prostate, 3016 prostate hyperplasia patients treated with this drug is 4 years relevant disposal ( surgical intervention ), urinary system such as transurethral resection of the prostate gland and other resection of the prostate, or need to insert the catheter acute urinary retention is evaluated.In this double - blind, randomized, placebo - controlled, multicenter study, treatment with this drug to the disposal of the overall risk of urinary system was reduced by 51%, with significant and sustained of prostate volume shrinking, and continuous maximum urinary flow rate increased and the symptoms improve.

 

 

Pharmacological effects

 

Finasteride is 4 - nitrogen compounds of steroid hormones, for specific Ⅱ type 5 alpha reductase inhibitors, inhibition of peripheral testosterone into dihydrotestosterone ( DHT ), reduce blood and prostate, skin, etc in DHT levels in the organization.The growth and development of the prostate and benign hyperplasia depends on DHT, finasteride by lowering blood and DHT levels in the prostate tissue and suppress hyperplasia of prostate and improve the related clinical symptoms of benign prostatic hyperplasia.

 

 

Indications

 

Used to treat prostatic hyperplasia.

 

 

Applicable people

 

BPH patients with enlarged prostate and lower urinary tract symptoms.

Patients with higher prostate volume ( 40ml ) and / or serum PSA levels ( PSA than 1.4ng/ml ) had better results

 

 

Specification

 

Test Items Specification Test Results
Description White or off-white crystalline powder Off-white crystalline powder
Specific rotation -56°~-60° -58.2°
Identification IR Matches with working standard Complies
HPLC
Solubility Freely soluble in chloroform and in alcohol;
Very slightly soluble in water
Conform
Heavy metals ≤10ppm <10ppm
Water ≤0.3% 0.22%
Residue on ignition ≤0.1% 0.05%
Relative material Maximum impurities≤0.5% 0.36%
Total impurities≤1.0% 0.52%
Assay 98.5~101.0% 99.59%
Conclusion The specification conform with Enterprise standard

 

 

Finasteride Hair Loss Medicine Raw Material 98319-26-7 White Powder For Prostatic Hyperplasia

Contact Details
Shanghai Poochun Industry Co.,Ltd

Send your inquiry directly to us (0 / 3000)